The Uncomfortable Reality: A 9% Surge in Healthcare Spending
As organizations finalize budgets for 2026, HR leaders and benefits managers are confronting a sobering projection: overall healthcare costs are expected to rise by approximately 9% next year. This increase compounds the inflationary pressures experienced in previous renewal cycles. For decision-makers juggling retention challenges, wage demands, and economic uncertainty, the annual benefits negotiation often feels like a frustrating exercise in absorbing higher costs or shifting a greater financial burden onto employees.
However, this year feels fundamentally different. The drivers of this inflation are shifting from incremental increases to structural acceleration, primarily fueled by two areas:
- Accelerating Pharmacy Trends: The widespread adoption of GLP-1 receptor agonists (used for both diabetes and weight management) has created a significant, rapidly expanding cost center.
- Specialty Drug Utilization: Spending on high-cost specialty care continues its upward trajectory, outpacing traditional pharmacy growth.
Chronic disease management remains the single largest determinant of long-term claims volatility. The pivotal question for employers is no longer *if* costs will rise, but whether the strategy will remain focused on managing margins, or pivot to addressing the root causes of escalating spend.
The GLP-1 Effect and the Specialty Drug Spiral
Medications like Ozempic (semaglutide) and Mounjaro (tirzepatide) have revolutionized treatment for type 2 diabetes and obesity, offering clinically transformative results for many patients. Yet, for self-funded employers, these therapies represent a substantial and often unpredictable expenditure, easily amounting to thousands of dollars per member annually.
The Gap Between Prescription and Sustainable Success
The challenge with high-cost, high-impact medications like GLP-1s often lies in the delivery model. Without coordinated oversight, prescribing can become reactive rather than holistic. Patients may receive these powerful medications without the necessary complementary support:
- Sustained behavioral modification counseling.
- Nutritional guidance tailored to the treatment phase.
- Longitudinal management to ensure adherence and efficacy.
When this support is missing, discontinuation rates can be high, leading to weight regain and the continuation of downstream, high-cost interventions. GLP-1s are merely the most visible component of a broader specialty drug spending challenge. High-cost specialist referrals and elevated emergency department (ED) utilization—often for issues manageable in lower-acuity settings—share a common underlying weakness: fragmented primary care.
The Throughput Problem: Why Primary Care Fails to Coordinate
The traditional primary care physician (PCP) model often incentivizes volume over value. Compensation structures frequently reward PCPs based on throughput—the sheer number of patient visits completed. This model inherently pressures physicians to move quickly, which severely limits the time available for crucial, in-depth management activities:
| Activity Limited by Volume-Based Care | Impact on Cost and Outcomes |
|---|---|
| Coordinating complex specialty referrals | Leads to unnecessary specialist utilization and fragmented treatment plans. |
| Monitoring medication adherence (e.g., for GLP-1s) | Increases risk of non-response, discontinuation, and eventual treatment failure. |
| Addressing behavioral health integration | Leaves root causes of chronic disease untreated, driving long-term claims volatility. |
| Supporting sustainable weight management | Reduces the long-term effectiveness of costly anti-obesity medications. |
In this high-throughput environment, complex interventions—like writing a prescription for a high-cost drug or ordering extensive testing—become the path of least resistance. While individually defensible, these actions, when uncoordinated, collectively drive up employer spending. Primary care, which should serve as the central navigator of a patient’s health journey, is instead often functioning as an overwhelmed gatekeeper.
Shifting Incentives: The Power of Robust Primary Care
Evidence strongly suggests that when primary care systems are strengthened, overall healthcare costs decrease, and patient outcomes improve. Research, including findings supported by organizations like the Commonwealth Fund, consistently links robust PCP access and strong physician-patient relationships to tangible financial benefits:
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Patients who maintain strong, continuous relationships with their primary care providers show lower overall mortality risk and significantly reduced total healthcare spending. For employers, this translates directly into fewer high-cost claims events and less volatility in annual budgeting.
When PCPs are compensated based on quality, coordination, and longitudinal patient health—rather than just visit volume—the clinical approach changes:
- Sustainable GLP-1 Use: Prescribing becomes integrated with lifestyle modification and ongoing monitoring, maximizing the medication’s impact.
- Proactive Chronic Disease Management: Conditions are managed before they escalate into acute crises requiring expensive specialist or ED intervention.
- Addressing Social Drivers: Behavioral health and social determinants of health are identified and addressed earlier, preventing downstream complications.
The Business Case for Investing Upstream
Chronic disease management is not just a claims issue; it’s a productivity issue. Poorly controlled diabetes, cardiovascular disease, and untreated mental health conditions are leading contributors to absenteeism, presenteeism (being at work but unproductive), and increased utilization of short-term disability.
Cost-shifting strategies, such as raising deductibles, are nearing their limit. While they may temporarily suppress utilization, they often delay necessary care, leading to more severe, expensive conditions later. HR leaders require strategies that stabilize spending while building employee trust.
Actionable Strategies: Reinforcing the Front Door of Care
Employers do not need to wait for sweeping federal reform to begin altering their cost trajectory. Many leading organizations are actively experimenting with models that shift investment upstream, preventing costly downstream escalation.
This involves asking foundational questions:
- GLP-1 Oversight: Instead of focusing solely on restricting access to semaglutide or tirzepatide, are our PCPs equipped and incentivized to ensure these medications are part of a comprehensive, sustainable treatment plan?
- Referral Management: Are unnecessary, high-cost specialist referrals occurring simply because primary care lacks the time or infrastructure for robust internal coordination?
- Data Integration: Are we leveraging tools to track patient engagement, symptom progression, and dosing consistency alongside their primary care records? (Platforms like Shotlee can provide the necessary infrastructure to log and monitor these critical data points, ensuring continuity between appointments.)
Reinforcing primary care—structurally and financially—is not merely a soft benefit enhancement. It is a direct cost-containment strategy built upon prevention, coordination, and trust. As leaders plan for 2026 and beyond, the most impactful investment may not be in negotiating specialist discounts, but in ensuring the front door of care is strong enough to prevent the most expensive outcomes from materializing.
Practical Takeaways for Benefits Leaders
To stabilize rising costs driven by specialty spend and GLP-1 utilization, focus on primary care infrastructure:
- Evaluate PCP Incentives: Favor value-based contracts or models that reward quality outcomes and care coordination over sheer visit volume.
- Demand Integrated Care: Ensure that high-cost prescriptions are bundled with mandatory behavioral health and nutritional support pathways.
- Invest in Data Continuity: Utilize digital health tools that allow patients and providers to seamlessly track progress, adherence, and side effects, ensuring that the investment in therapies like GLP-1s is maximized.
Conclusion
The current trajectory of healthcare spending, heavily influenced by powerful new medications and fragmented care delivery, is unsustainable. While GLP-1s offer incredible clinical potential, realizing their long-term value—and controlling overall spend—requires a fundamental shift. By reinforcing primary care as the central coordinator, employers can move beyond reactive cost management to build a foundation of proactive, efficient, and higher-quality care for their workforce.